| Name | Title | Contact Details |
|---|
The Ideal Protein Method is medically designed & developed, being consistent with evidence-based guidelines for weight loss management and maintenance. It is a weight loss solution for the obese and overweight patient, including those with metabolic syndrome. Ideal Protein puts forward a proven, four-part method that enables safe, effective weight loss, with a healthy lifestyle approach and a structured maintenance program to sustain weight loss success. The method targets the root causes of weight gain by reversing the imbalance of insulin that occurs with the typical Western diet. A healthier lifestyle education is a key component of all phases of the Ideal Protein Weight Loss Method, which features personalized, one-on-one coaching and a diet plan to promote losing fat while maintaining lean muscle mass. For a hospital, medical group or private medical practice, the Ideal Protein Method is a comprehensive turnkey program with no costs for training and implementation, and no long-term commitment. Offered through healthcare practitioners, trained clinics and centers, the Ideal Protein Weight Loss Method and products are now available in more than 3,000 clinics and centers throughout North America. Research demonstrating the results of the Ideal Protein Weight Loss Method has been presented at leading medical conferences such as the 9th Annual Obesity Summit at the Cleveland Clinic and the Annual Scientific Meeting of the National Obesity Society. For information on Ideal Protein, please visit our website. For details about incorporating Ideal Protein into your medical practice, visit our practitioner information pages for Physicians and Pharmacists.
Flow Sciences Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Elixir Medical Corporation, a privately-funded company based in Milpitas, California, develops next-generation platforms to treat coronary and peripheral artery disease that are designed to restore the adaptive remodeling and pulsatile motion capabilities of the blood vessel. The company`s mission is to transform the care of patients with heart and vascular disease through innovation.
Calibrate is a Carrboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A Global Total Solutions Provider Dentsply Sirona is the world`s largest manufacturer of professional dental products and technologies, empowering dental professionals to provide better, safer and faster dental care. Our products and solutions include leading positions and platforms across consumables, equipment, technology, and specialty products. Dentsply Sirona is one global team that brings out the best in our people, lives and breathes high performance and personal accountability, acts with uncompromising integrity, improves the practice of dentistry with an unrelenting commitment to our customers and demonstrates a passion for innovation that shapes the dental industry. As The Dental Solutions Company™, Dentsply Sirona provides dental professionals a comprehensive end-to-end solutions offering. This offering includes some of the best-known and established brands in the industry. We develop, manufacture and market a complete line of dental and oral health products, including general dental supplies and devices, CAD/CAM restoration systems (CEREC and inLab), a full suite of dental restorative products, digital intra-oral, panoramic and 3D imaging systems, dental treatment centers, hand pieces, hygiene systems, and dental specialty products in orthodontics, endodontics and implants. Additionally, our global consumable healthcare product team provides innovative urological and surgical solutions designed to improve quality of life for patients. We are proud to be a preferred partner for dental practices, clinics, dental laboratories and authorized distributors worldwide. Dentsply Sirona`s Global Headquarters is located in York, Pennsylvania, and the International Headquarters is based in Salzburg, Austria. Our shares are listed in the United States on NASDAQ under the symbol XRAY, and in the 12 months ended December 31, 2015, the combined company had pro-forma revenue of approximately $4 billion.